Cargando…

Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-Resistant Shigella dysenteriae and Staphylococcus aureus

Developing new strategies to replace or supplement antibiotics to combat bacterial infection is a pressing task in the field of microbiological research. In this study, we report a lytic enzyme named P9ly deriving from the bacteriophage PSD9 that could infect multidrug-resistant Shigella. This enzym...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feng, Xiao, Yao, Lu, Yao, Deng, Zheng-Yu, Deng, Xian-Yu, Lin, Lian-Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882861/
https://www.ncbi.nlm.nih.gov/pubmed/35237249
http://dx.doi.org/10.3389/fmicb.2022.821989
_version_ 1784659792540729344
author Wang, Feng
Xiao, Yao
Lu, Yao
Deng, Zheng-Yu
Deng, Xian-Yu
Lin, Lian-Bing
author_facet Wang, Feng
Xiao, Yao
Lu, Yao
Deng, Zheng-Yu
Deng, Xian-Yu
Lin, Lian-Bing
author_sort Wang, Feng
collection PubMed
description Developing new strategies to replace or supplement antibiotics to combat bacterial infection is a pressing task in the field of microbiological research. In this study, we report a lytic enzyme named P9ly deriving from the bacteriophage PSD9 that could infect multidrug-resistant Shigella. This enzyme was identified through whole-genome sequencing of PSD9. The results show that P9ly contains a conserved T4-like_lys domain and belongs to the phage lysozyme family. Recombinant P9ly obtained from protein purification presented biological activity and could digest bacterial cell walls (CW), resulting in the destruction of cell structure and leakage of intracellular components. Furthermore, P9ly exhibited bacteriolytic and bactericidal activity on different strains, especially multidrug-resistant Gram-negative Shigella dysenteriae and Gram-positive Staphylococcus aureus. Additionally, combined use of P9ly with ceftriaxone sodium (CRO) could decrease necessary dose of the antibiotic used and improve the antibacterial effect. In summary, under the current backdrop of extensive antibiotic usage and the continuous emergence of bacterial resistance, this study provides an insight into developing bacteriophage-based antibacterial agents against both Gram-negative and Gram-positive pathogens.
format Online
Article
Text
id pubmed-8882861
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88828612022-03-01 Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-Resistant Shigella dysenteriae and Staphylococcus aureus Wang, Feng Xiao, Yao Lu, Yao Deng, Zheng-Yu Deng, Xian-Yu Lin, Lian-Bing Front Microbiol Microbiology Developing new strategies to replace or supplement antibiotics to combat bacterial infection is a pressing task in the field of microbiological research. In this study, we report a lytic enzyme named P9ly deriving from the bacteriophage PSD9 that could infect multidrug-resistant Shigella. This enzyme was identified through whole-genome sequencing of PSD9. The results show that P9ly contains a conserved T4-like_lys domain and belongs to the phage lysozyme family. Recombinant P9ly obtained from protein purification presented biological activity and could digest bacterial cell walls (CW), resulting in the destruction of cell structure and leakage of intracellular components. Furthermore, P9ly exhibited bacteriolytic and bactericidal activity on different strains, especially multidrug-resistant Gram-negative Shigella dysenteriae and Gram-positive Staphylococcus aureus. Additionally, combined use of P9ly with ceftriaxone sodium (CRO) could decrease necessary dose of the antibiotic used and improve the antibacterial effect. In summary, under the current backdrop of extensive antibiotic usage and the continuous emergence of bacterial resistance, this study provides an insight into developing bacteriophage-based antibacterial agents against both Gram-negative and Gram-positive pathogens. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8882861/ /pubmed/35237249 http://dx.doi.org/10.3389/fmicb.2022.821989 Text en Copyright © 2022 Wang, Xiao, Lu, Deng, Deng and Lin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Wang, Feng
Xiao, Yao
Lu, Yao
Deng, Zheng-Yu
Deng, Xian-Yu
Lin, Lian-Bing
Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-Resistant Shigella dysenteriae and Staphylococcus aureus
title Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-Resistant Shigella dysenteriae and Staphylococcus aureus
title_full Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-Resistant Shigella dysenteriae and Staphylococcus aureus
title_fullStr Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-Resistant Shigella dysenteriae and Staphylococcus aureus
title_full_unstemmed Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-Resistant Shigella dysenteriae and Staphylococcus aureus
title_short Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-Resistant Shigella dysenteriae and Staphylococcus aureus
title_sort bacteriophage lytic enzyme p9ly as an alternative antibacterial agent against antibiotic-resistant shigella dysenteriae and staphylococcus aureus
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882861/
https://www.ncbi.nlm.nih.gov/pubmed/35237249
http://dx.doi.org/10.3389/fmicb.2022.821989
work_keys_str_mv AT wangfeng bacteriophagelyticenzymep9lyasanalternativeantibacterialagentagainstantibioticresistantshigelladysenteriaeandstaphylococcusaureus
AT xiaoyao bacteriophagelyticenzymep9lyasanalternativeantibacterialagentagainstantibioticresistantshigelladysenteriaeandstaphylococcusaureus
AT luyao bacteriophagelyticenzymep9lyasanalternativeantibacterialagentagainstantibioticresistantshigelladysenteriaeandstaphylococcusaureus
AT dengzhengyu bacteriophagelyticenzymep9lyasanalternativeantibacterialagentagainstantibioticresistantshigelladysenteriaeandstaphylococcusaureus
AT dengxianyu bacteriophagelyticenzymep9lyasanalternativeantibacterialagentagainstantibioticresistantshigelladysenteriaeandstaphylococcusaureus
AT linlianbing bacteriophagelyticenzymep9lyasanalternativeantibacterialagentagainstantibioticresistantshigelladysenteriaeandstaphylococcusaureus